眾生藥業(002317.SZ):子公司獲得歐洲專利證書 涉作為PPAR激動劑的吡咯烷衍生物
格隆匯6月12日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)收到歐洲專利局(European Patent Office)頒發的專利證書,專利名稱為PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST(作為PPAR激動劑的吡咯烷衍生物)。
該專利是公司控股子公司眾生睿創在肝病領域佈局的第二個創新藥ZSP0678項目的化合物專利,屬於該項目的核心專利。ZSP0678是眾生睿創研發的具有明確作用機制並具有自主知識產權的用於治療非酒精性脂肪性肝炎(NASH)和原發性膽汁性膽管炎(PBC)的創新藥物。目前,ZSP0678片用於治療NASH臨牀試驗已獲得國家藥品監督管理局(NMPA)的批准,在中國健康志願者的I期臨牀試驗已經啟動,並已完成首例志願者入組和給藥,臨牀試驗的工作正按計劃積極推進中;ZSP0678片新增適應症“治療原發性膽汁性膽管炎(PBC)”獲得國家藥品監督管理局核發的《臨牀試驗通知書》,同意ZSP0678新增適應症進行臨牀試驗。
後續公司將結合項目開發計劃啟動該專利歐洲指定國生效程序。ZSP0678項目化合物核心專利目前已獲得包括美國、澳大利亞、俄羅斯、歐洲等國家/地區的專利授權,ZSP0678項目的全球知識產權保護體系逐漸完善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.